|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||434.624 g·mol−1|
|3D model (JSmol)|
|(what is this?)|
SER-601 (COR-167) is a drug which acts as a potent and selective cannabinoid CB2 receptor agonist, based on a quinolone-3-carboxylic acid core structure, with 190 times selectivity for CB2 over the related CB1 receptor. It has analgesic effects in animal studies, as well as neuroprotective effects, but without a "cannabis high" due to it's low affinity for CB1. A number of related compounds are known, almost all of which have high selectivity for CB2.
- Contartese, A.; Valoti, M.; Corelli, F.; Pasquini, S.; Mugnaini, C.; Pessina, F.; Aldinucci, C.; Sgaragli, G.; Frosini, M. (2012). "A novel CB2 agonist, COR167, potently protects rat brain cortical slices against OGD and reperfusion injury". Pharmacological Research. 66 (6): 555–563. doi:10.1016/j.phrs.2012.08.003. PMID 23036353.
- Pasquini S, et al. (August 2008). "Investigations on the 4-quinolone-3-carboxylic acid motif. 2. Synthesis and structure-activity relationship of potent and selective cannabinoid-2 receptor agonists endowed with analgesic activity in vivo". Journal of Medicinal Chemistry. 51 (16): 5075–84. doi:10.1021/jm800552f. PMID 18680276.
- Pasquini S, et al. (August 2010). "Investigations on the 4-quinolone-3-carboxylic acid motif. 3. Synthesis, structure-affinity relationships, and pharmacological characterization of 6-substituted 4-quinolone-3-carboxamides as highly selective cannabinoid-2 receptor ligands". Journal of Medicinal Chemistry. 53 (16): 5915–28. doi:10.1021/jm100123x. PMID 20718492.